Chiesi supports sustainable inhaler project

27 April 2021

Family-owned Italian drugmaker Chiesi has teamed up with two small to medium-sized enterprise (SME) companies in an initiative with government-backed funding agency Innovate UK to encourage research into inhaler sustainability.

The companies that came up with a winning proposal came from the companies Reply and Dsposal, which are researching ways to minimize or eliminate the use of plastic in pressurised metered dose inhalers through a potential redesign of the plastic actuator.

"Global inhaler use is on the rise and we need to find ways to minimize their impact for a greener future"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK